MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
China Pharma Holdings Operating Income 2011-2025 | CPHI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income China Pharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.59 M | -2.75 M | -3.55 M | -2.86 M | -2.58 M | -20.4 M | -10.4 M | -18.7 M | -8.16 M | -14.3 M | -38.8 M | -18.6 M | 5.91 M | 22 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22 M | -38.8 M | -8.41 M |
Quarterly Operating Income China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -628 K | -652 K | -759 K | - | -1.09 M | -1.39 M | -916 K | - | -714 K | -456 K | -397 K | - | -689 K | -780 K | -912 K | - | -762 K | -753 K | -696 K | - | -952 K | 75 K | -599 K | - | -645 K | -753 K | -334 K | - | -1.93 M | -864 K | -141 K | - | -2.06 M | -2.13 M | -803 K | - | -1.55 M | -2.22 M | -1.32 M | - | 3.19 M | 1.44 M | -3.76 M | - | -5.99 M | -8.53 M | -2.34 M | - | -2.69 M | -4.76 M | -3 M | - | 1.62 M | 2.21 M | 3.41 M | - | 5.96 M | 5.76 M | 5.34 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.96 M | -8.53 M | -665 K |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 0.66 | -0.02 % | $ 46.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.31 | -6.43 % | $ 141 M |  Canada |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.57 | -1.72 % | $ 86.3 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 12.63 | 0.72 % | $ 647 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.58 | 0.19 % | $ 2.05 B |  France |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
-34.4 M | $ 6.85 | 0.59 % | $ 425 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 50.16 | 2.05 % | $ 1.64 B | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 5.87 | 2.09 % | $ 773 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 26.02 | 1.09 % | $ 1.2 B | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 7.18 | -1.91 % | $ 2.62 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.76 | 1.15 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.2 | -1.41 % | $ 59.1 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.6 | 2.45 % | $ 138 M | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.81 | -0.81 % | $ 18.9 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 13.75 | 0.51 % | $ 1.89 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | $ 0.62 | -10.48 % | $ 9.82 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.77 | -0.56 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.9 | - | $ 241 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.64 | 1.68 % | $ 4.52 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.6 | 1.78 % | $ 28.7 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 10.15 | -3.61 % | $ 6.27 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.7 | 3.66 % | $ 17.7 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.34 | 0.86 % | $ 316 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.59 | -4.22 % | $ 6.86 M | USA |
 |
Viatris
VTRS
|
1.61 B | $ 12.24 | 1.83 % | $ 14.8 B | USA |
 |
Zomedica Corp.
ZOM
|
-31.6 M | - | -0.21 % | $ 98 M | USA |